Evidence map›Paper›PMID 37928535›Full record

ArticleFrontiers in immunology2023

Myeloid cell ACE shapes cellular metabolism and function in PCSK-9 induced atherosclerosis.

DuoYao Cao, Suguru Saito, LiMin Xu, Wei Fan, Xiaomo Li, Faizan Ahmed, Predrag Jovanovic, Tomohiro Shibata, Mingtian Che, Ellen A Bernstein and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

DuoYao Cao *Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Suguru Saito *Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
LiMin Xu *Department of Neurosurgery, Shenzhen Entry-Exit Frontier Inspection Hospital, Shenzhen, China.
Wei Fan *Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Xiaomo LiDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Faizan AhmedDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Predrag JovanovicDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Tomohiro ShibataDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Mingtian CheBiobank and Pathology Shared Resource, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Ellen A BernsteinDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Jorge GianniDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Ajit S DivakaruniDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, CA, United States.
Derick Okwan-DuoduDepartment of Pathology, Faculty of Medicine, Stanford University, San Jose, CA, United States.
Zakir KhanDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Celine E RieraDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Fanfan ChenDepartment of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
Kenneth E BernsteinDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Cedars-Sinai Medical Center · USShenzhen Entry-Exit Inspection and Quarantine Bureau · CNShenzhen Second People's Hospital · CNStanford University · USUniversity of California, Los Angeles · US

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrea L Hevener · 2003 to 2026
$40.4M
The Role of Inflammation in Cardiovascular DiseaseP01HL129941 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRISON, DAVID G · 2016 to 2020
$12.4M
ACE and myeloid cell metabolismR01AI164519 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI KENNETH E BERNSTEIN · 2022 to 2026
$3.1M
Understanding How Metabolic Cofactors Control Cell Function and FateR35GM138003 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Ajit Divakaruni · 2020 to 2026
$2.8M
Supplemental Grant: Increased neutrophil function in Alzheimer's diseaseR01AI134714 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI BERNSTEIN, KENNETH E · 2018 to 2021
$2.1M
The role of angiotensin-converting enzyme in renal inflammation, kidney injury and sodium retention during diabetic nephropathyR01HL142672 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI BERNSTEIN, KENNETH E · 2018 to 2021
$1.7M
Maladaptive Inflammation Impairs Collateral Vessel Formation in Sickle Cell DiseaseK99HL141638 · NHLBI · EMORY UNIVERSITY · PI OKWAN-DUODU, DERICK · 2019 to 2020
$210k
NHLBI NIH HHS K99 HL141638NHLBI NIH HHS P01 HL129941NHLBI NIH HHS R01 HL142672NIAID NIH HHS R01 AI134714NIAID NIH HHS R01 AI164519NIDDK NIH HHS P30 DK063491NIGMS NIH HHS R35 GM138003
6 · The paper itself

Abstract

The pathogenesis of atherosclerosis is defined by impaired lipid handling by macrophages which increases intracellular lipid accumulation. This dysregulation of macrophages triggers the accumulation of apoptotic cells and chronic inflammation which contributes to disease progression. We previously reported that mice with increased macrophage-specific angiotensin-converting enzyme, termed ACE10/10 mice, resist atherosclerosis in an adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-induced model. This is due to increased lipid metabolism by macrophages which contributes to plaque resolution. However, the importance of ACE in peripheral blood monocytes, which are the primary precursors of lesional-infiltrating macrophages, is still unknown in atherosclerosis. Here, we show that the ACE-mediated metabolic phenotype is already triggered in peripheral blood circulating monocytes and that this functional modification is directly transferred to differentiated macrophages in ACE10/10 mice. We found that Ly-6Clo monocytes were increased in atherosclerotic ACE10/10 mice. The monocytes isolated from atherosclerotic ACE10/10 mice showed enhanced lipid metabolism, elevated mitochondrial activity, and increased adenosine triphosphate (ATP) levels which implies that ACE overexpression is already altered in atherosclerosis. Furthermore, we observed increased oxygen consumption (VO2), respiratory exchange ratio (RER), and spontaneous physical activity in ACE10/10 mice compared to WT mice in atherosclerotic conditions, indicating enhanced systemic energy consumption. Thus, ACE overexpression in myeloid lineage cells modifies the metabolic function of peripheral blood circulating monocytes which differentiate to macrophages and protect against atherosclerotic lesion progression due to better lipid metabolism.

Indexed as

AtherosclerosisProprotein Convertase 9AnimalsLipidsMiceMyeloid CellsLipidsProprotein Convertase 9angiotensin converting enzyme (ACE)atherosclerosislipid metabolismLy-6Clomacrophagesmonocytes

Identifiers

PMID37928535
PMCPMC10623052
OpenAlexW4387818048

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.